Yongmei Ding

525 total citations
13 papers, 440 citations indexed

About

Yongmei Ding is a scholar working on Oncology, Molecular Biology and Biomaterials. According to data from OpenAlex, Yongmei Ding has authored 13 papers receiving a total of 440 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Molecular Biology and 5 papers in Biomaterials. Recurrent topics in Yongmei Ding's work include Nanoparticle-Based Drug Delivery (4 papers), CAR-T cell therapy research (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Yongmei Ding is often cited by papers focused on Nanoparticle-Based Drug Delivery (4 papers), CAR-T cell therapy research (4 papers) and Pancreatic and Hepatic Oncology Research (2 papers). Yongmei Ding collaborates with scholars based in China and United States. Yongmei Ding's co-authors include Qijun Qian, Yuan Fang, Yajun Zhang, Pei Wang, Wei Zhou, Shuyan Meng, Wěi Li, Xintao Yang, Jiangtao Wang and Zhiwei Zhang and has published in prestigious journals such as Nanotechnology, Cell Death and Disease and Powder Technology.

In The Last Decade

Yongmei Ding

13 papers receiving 427 citations

Peers

Yongmei Ding

ONCOL

IMMUN

BIOMA

Meijia Yang China

Sarah Nietzer Germany

Armin Ahmadi United States

Feifei Qi China

Isabella Monia Montagner Italy

Xueru Song China

Ramamurthy Gopalakrishnan United States

Neda Dadgar United States

Johanna Kühnemundt Germany

Anliang Huang China

Meijia Yang China

Yongmei Ding

350 ×1.4

ONCOL

145 ×0.8

122 ×1.0

191 ×2.0

IMMUN

53 ×0.6

BIOMA

Citations per year, relative to Yongmei Ding Yongmei Ding (= 1×) peers Meijia Yang

Countries citing papers authored by Yongmei Ding

Since Specialization

Citations

This map shows the geographic impact of Yongmei Ding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yongmei Ding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yongmei Ding more than expected).

Fields of papers citing papers by Yongmei Ding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yongmei Ding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yongmei Ding. The network helps show where Yongmei Ding may publish in the future.

Co-authorship network of co-authors of Yongmei Ding

This figure shows the co-authorship network connecting the top 25 collaborators of Yongmei Ding. A scholar is included among the top collaborators of Yongmei Ding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yongmei Ding. Yongmei Ding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Yang, Xijing, et al.. (2023). Hypoxia-induced circRTN4IP1 promotes progression and glycolysis of hepatocellular carcinoma cells. Functional & Integrative Genomics. 23(4). 339–339. 1 indexed citations

Zhang, Yajun, et al.. (2021). Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy. Journal of Translational Medicine. 19(1). 82–82. 20 indexed citations

Zhang, Yajun, Zhiwei Zhang, Yongmei Ding, et al.. (2021). Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology. 147(12). 3725–3734. 116 indexed citations

Ye, Zhenlong, Yongmei Ding, Zhuo Chen, et al.. (2019). Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. 2 indexed citations

Li, He, Yao Huang, Chao Wang, et al.. (2018). Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice. Cell Death and Disease. 9(2). 177–177. 89 indexed citations

Ye, Zhenlong, Yongmei Ding, Zhuo Chen, et al.. (2018). Detecting and phenotyping of aneuploid circulating tumor cells in patients with various malignancies. Cancer Biology & Therapy. 20(4). 546–551. 34 indexed citations

Wang, Yingying, Xiaohong Wang, Yongmei Ding, et al.. (2017). Novel sodium lignosulphonate assisted synthesis of well dispersed Fe3O4 microspheres for efficient adsorption of copper (II). Powder Technology. 325. 597–605. 39 indexed citations

Ye, Zhenlong, Yongmei Ding, Linfang Li, et al.. (2017). Mesothelin-targeting chimeric antigen receptor–modified T cells by piggyBac transposon system suppress the growth of bile duct carcinoma. Tumor Biology. 39(4). 3726131194–3726131194. 17 indexed citations

Yi, Xianghua, Yongmei Ding, Yu Zeng, et al.. (2011). Magnetic Resonance Imaging Contrast Agent: cRGD-Ferric Oxide Nanometer Particle and Its Role in the Diagnosis of Tumor. Journal of Nanoscience and Nanotechnology. 11(5). 3800–3807. 3 indexed citations

10.

Li, Wei, Bo Su, Shuyan Meng, et al.. (2011). RGD-targeted paramagnetic liposomes for early detection of tumor: In vitro and in vivo studies. European Journal of Radiology. 80(2). 598–606. 24 indexed citations

11.

Meng, Shuyan, Wěi Li, Yongmei Ding, et al.. (2010). Enhanced antitumor effect of novel dual-targeted paclitaxel liposomes. Nanotechnology. 21(41). 415103–415103. 49 indexed citations

12.

Meng, Shuyan, Bo Su, Wěi Li, et al.. (2010). Integrin-targeted paclitaxel nanoliposomes for tumor therapy. Medical Oncology. 28(4). 1180–1187. 42 indexed citations

13.

Zhou, Caicun, Liang Tang, Xiao‐Jun Yang, et al.. (2010). [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].. PubMed. 33(5). 354–8. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact